IGHE and allergic asthma: Blocking thymic stromal lymphopoietin (TSLP) with tezepelumab reduced serum total IgE levels, improved FEF25–75 as well as attenuated the maximum % fall in FEV1 during the LAR in individuals with mild allergic asthma [49,50,51].